Nektar Therapeutics (NKTR) Interest & Investment Income (2010 - 2026)
Nektar Therapeutics' quarterly Interest & Investment Income came in at $4.2 million in Q1 2026, up 47.6% year-on-year from $2.9 million in Q1 2025, and up 52.81% quarter-over-quarter from $2.8 million in Q4 2025.
Nektar Therapeutics has reported Interest & Investment Income for 9 years, with the latest figure at $4.2 million in Q1 2026.
- For the quarter ending Q1 2026, Interest & Investment Income rose 47.6% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $11.8 million (down 10.25% YoY), and the FY2025 full-year result was $10.4 million, down 28.01% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $4.2 million, up from $2.8 million in the prior quarter.
- The five-year high for Interest & Investment Income was $5.2 million in Q3 2023, with the low at $2.0 million in Q2 2025.
- Average Interest & Investment Income over 4 years is $3.7 million, with a median of $3.9 million recorded in 2024.
- Year-over-year, Interest & Investment Income slumped 49.53% in 2025 and jumped 47.6% in 2026.
- Tracing NKTR's Interest & Investment Income over 4 years: stood at $4.6 million in 2023, then sank by 36.28% to $2.9 million in 2024, then declined by 5.64% to $2.8 million in 2025, then jumped by 52.81% to $4.2 million in 2026.
- The last three Interest & Investment Income figures came in at $4.2 million (Q1 2026), $2.8 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Nektar Therapeutics | 1.60 Bn | 1.04 Bn | 3.16 Mn | 4.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.24 Mn |
| Dec 31, 2025 | 2.78 Mn |
| Sep 30, 2025 | 2.82 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 2.87 Mn |
| Dec 31, 2024 | 2.94 Mn |
| Sep 30, 2024 | 3.44 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Mar 31, 2024 | 4.22 Mn |
| Dec 31, 2023 | 4.62 Mn |
| Sep 30, 2023 | 5.21 Mn |
| Jun 30, 2023 | 4.85 Mn |
| Mar 31, 2023 | 4.34 Mn |
| Sep 30, 2014 | 133,000.00 |
| Jun 30, 2014 | 132,000.00 |
| Mar 31, 2014 | 134,000.00 |
| Dec 31, 2013 | 93,000.00 |
| Sep 30, 2013 | 116,000.00 |
| Jun 30, 2013 | 209,000.00 |
| Mar 31, 2013 | 314,000.00 |
| Dec 31, 2012 | 450,000.00 |
| Sep 30, 2012 | 603,000.00 |
| Jun 30, 2012 | 630,000.00 |
| Mar 31, 2012 | 632,000.00 |
| Dec 31, 2011 | 661,000.00 |
| Sep 30, 2011 | 622,000.00 |
| Jun 30, 2011 | 529,000.00 |
| Mar 31, 2011 | 432,000.00 |
| Dec 31, 2010 | 320,000.00 |
| Sep 30, 2010 | 369,000.00 |
| Jun 30, 2010 | 393,000.00 |
| Mar 31, 2010 | 463,000.00 |